Han Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Han Lin has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Chun‐Man Wang
Department of Anesthesiology, Critical Care and Pain Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China
2 shared publicationsJiang‐Ping Zhou
Department of Anesthesiology, Critical Care and Pain Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China
2 shared publicationsJin Liu
Department of Anesthesiology, Critical Care and Pain Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China
2 shared publications- Chun‐Long Zuo
Department of Anesthesiology, Critical Care and Pain Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China
1 shared publication Dianne O. Hardy
Population Council, New York, NY, USA
1 shared publicationGuo-Xin Hu
Wenzhou Medical College, Wenzhou, China
1 shared publication
Latest Publications
- Open Access
- 1 November 2019
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 13, 3785-3798
Subarachnoid and epidural dexmedetomidine for the prevention of post-anesthetic shivering: a meta-analysis and systematic review
Background: Post-anesthetic shivering incurs discomfort to patients or even exacerbates their condition. However, no ideal drug has been well established for preventing post-anesthetic shivering. Currently, subarachnoid and epidural dexmedetomidine have demonstrated to have an anti-shivering effect. Methods: An electronic search was conducted to identify randomized placebo-controlled trials reporting shivering and then compared subarachnoid and epidural dexmedetomidine with placebo in adults undergoing selective surgery. Data assessment and pooling were analyzed by Review Manager 5.3, STATA 15.0 and GRADE-pro 3.6 software. Results: Twenty-two studies (1389 patients) were subjected to this meta-analysis. The incidence of post-anesthetic shivering decreased from 20.10% in the placebo group to 10.30% in the dexmedetomidine group (RR, 0.48; 95% CI, 0.39–0.59; Z=6.86, P5 μg showed significantly superior anti-shivering effects than that of ≤5 μg. Subarachnoid and epidural dexmedetomidine increased the incidence of bradycardia, had no impact on nausea and vomiting, shortened the onset of block and lengthened the duration of block and analgesia. However, its effect on hypotension and sedation remained uncertain. The overall risk of bias was relatively low. The level of evidence was high, and the recommendation of voting results was strong. Conclusion: Dexmedetomidine as a subarachnoid and epidural adjunct drug could decrease the incidence of post-anesthetic shivering in a dose-dependent manner. However, caution should be taken in patients with original bradycardia.
- 1 November 2019
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 13, 3785-3798
Open AccessSubarachnoid and epidural dexmedetomidine for the prevention of post-anesthetic shivering: a meta-analysis and systematic review
Background: Post-anesthetic shivering incurs discomfort to patients or even exacerbates their condition. However, no ideal drug has been well established for preventing post-anesthetic shivering. Currently, subarachnoid and epidural dexmedetomidine have demonstrated to have an anti-shivering effect. Methods: An electronic search was conducted to identify randomized placebo-controlled trials reporting shivering and then compared subarachnoid and epidural dexmedetomidine with placebo in adults undergoing selective surgery. Data assessment and pooling were analyzed by Review Manager 5.3, STATA 15.0 and GRADE-pro 3.6 software. Results: Twenty-two studies (1389 patients) were subjected to this meta-analysis. The incidence of post-anesthetic shivering decreased from 20.10% in the placebo group to 10.30% in the dexmedetomidine group (RR, 0.48; 95% CI, 0.39–0.59; Z=6.86, P5 μg showed significantly superior anti-shivering effects than that of ≤5 μg. Subarachnoid and epidural dexmedetomidine increased the incidence of bradycardia, had no impact on nausea and vomiting, shortened the onset of block and lengthened the duration of block and analgesia. However, its effect on hypotension and sedation remained uncertain. The overall risk of bias was relatively low. The level of evidence was high, and the recommendation of voting results was strong. Conclusion: Dexmedetomidine as a subarachnoid and epidural adjunct drug could decrease the incidence of post-anesthetic shivering in a dose-dependent manner. However, caution should be taken in patients with original bradycardia.
- Open Access
- 12 March 2018
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 24 (10) , 940-946
Low‐dose curcumin stimulates proliferation of rat embryonic neural stem cells through glucocorticoid receptor and STAT3
Summary: Aims: This study was to determine whether curcumin had any effect on the proliferation of neural stem cell (NSC), analyze the expression of glucocorticoid receptor (GR), signal transducer and activator of transcription 3 (STAT3), and Notch1 at transcription and protein level, and discuss the related mechanisms.Methods and results: NSCs were harvested from E15 SD rat brain and cultured. All experiments were performed at the second passage. Cell cytotoxicity, cell viability, and proliferation assays were used to figure out the optimal concentration of curcumin, which can be used for the protein and mRNA studies. The results showed that by downregulation of GR and STAT3 expression, 0.5 μmol L−1 curcumin exhibited the most pronounced effect in promoting the proliferation of NSCs, which were also induced by antagonists of GR and STAT3, but was inhibited by GR agonist.Conclusion: This study shows that low‐dose curcumin stimulates the proliferation of NSCs, which is probably by inhibiting the mRNA and protein expressions of GR and directly or indirectly regulating the STAT3 via the synergistic effect of GR and STAT3 pathways and its related signal pathways.
- 12 March 2018
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 24 (10) , 940-946
Open AccessLow‐dose curcumin stimulates proliferation of rat embryonic neural stem cells through glucocorticoid receptor and STAT3
Summary: Aims: This study was to determine whether curcumin had any effect on the proliferation of neural stem cell (NSC), analyze the expression of glucocorticoid receptor (GR), signal transducer and activator of transcription 3 (STAT3), and Notch1 at transcription and protein level, and discuss the related mechanisms.Methods and results: NSCs were harvested from E15 SD rat brain and cultured. All experiments were performed at the second passage. Cell cytotoxicity, cell viability, and proliferation assays were used to figure out the optimal concentration of curcumin, which can be used for the protein and mRNA studies. The results showed that by downregulation of GR and STAT3 expression, 0.5 μmol L−1 curcumin exhibited the most pronounced effect in promoting the proliferation of NSCs, which were also induced by antagonists of GR and STAT3, but was inhibited by GR agonist.Conclusion: This study shows that low‐dose curcumin stimulates the proliferation of NSCs, which is probably by inhibiting the mRNA and protein expressions of GR and directly or indirectly regulating the STAT3 via the synergistic effect of GR and STAT3 pathways and its related signal pathways.
- Open Access
- 17 January 2018
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 24 (3) , 212-221
Isoflurane anesthesia in aged mice and effects of A1 adenosine receptors on cognitive impairment
Summary: Aims: Isoflurane may not only accelerate the process of Alzheimer's disease (AD), but increase the risk of incidence of postoperative cognitive dysfunction (POCD). However, the underlying mechanisms remain unknown. This study was designed to investigate whether isoflurane contributed to the POCD occurrence through A1 adenosine receptor (A1AR) in aged mice.Methods: We assessed cognitive function of mice with Morris water maze (MWM) and then measured expression level of two AD biomarkers (P‐tau and Aβ) and a subtype of the NMDA receptor (NR2B) in aged wild‐type (WT) and homozygous A1 adenosine receptor (A1AR) knockout (KO) mice at baseline and after they were exposed to isoflurane (1.4% for 2 hours).Results: For cognitive test, WT mice with isoflurane exposure performed worse than the WT mice without isoflurane exposure. However, A1AR KO mice with isoflurane exposure performed better than WT mice with isoflurane exposure. WT mice exposed to isoflurane had increased levels of Aβ and phosphorylated tau (P‐tau). Levels of Aβ and P‐tau were decreased in A1AR KO mice, whereas no differences were noted between KO mice with and without isoflurane exposure. NR2B expression was inversely related to that of P‐tau, with no differences found between KO mice with and without isoflurane exposure.Conclusions: We found an association between isoflurane exposure, impairment of spatial memory, decreasing level of NR2B, and increasing levels of A‐beta and P‐tau, presumably via the activation of the A1A receptor.
- 17 January 2018
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 24 (3) , 212-221
Open AccessIsoflurane anesthesia in aged mice and effects of A1 adenosine receptors on cognitive impairment
Summary: Aims: Isoflurane may not only accelerate the process of Alzheimer's disease (AD), but increase the risk of incidence of postoperative cognitive dysfunction (POCD). However, the underlying mechanisms remain unknown. This study was designed to investigate whether isoflurane contributed to the POCD occurrence through A1 adenosine receptor (A1AR) in aged mice.Methods: We assessed cognitive function of mice with Morris water maze (MWM) and then measured expression level of two AD biomarkers (P‐tau and Aβ) and a subtype of the NMDA receptor (NR2B) in aged wild‐type (WT) and homozygous A1 adenosine receptor (A1AR) knockout (KO) mice at baseline and after they were exposed to isoflurane (1.4% for 2 hours).Results: For cognitive test, WT mice with isoflurane exposure performed worse than the WT mice without isoflurane exposure. However, A1AR KO mice with isoflurane exposure performed better than WT mice with isoflurane exposure. WT mice exposed to isoflurane had increased levels of Aβ and phosphorylated tau (P‐tau). Levels of Aβ and P‐tau were decreased in A1AR KO mice, whereas no differences were noted between KO mice with and without isoflurane exposure. NR2B expression was inversely related to that of P‐tau, with no differences found between KO mice with and without isoflurane exposure.Conclusions: We found an association between isoflurane exposure, impairment of spatial memory, decreasing level of NR2B, and increasing levels of A‐beta and P‐tau, presumably via the activation of the A1A receptor.
- Open Access
- 1 May 2008
- Published by Oxford University Press (OUP) in Biology of Reproduction
- Vol. 78 (Suppl_1) , 142
11Keto-Testosterone as Androgen Contraceptive with Anti-Metabolic Benefits by Modulating 11β-Hydroxysteroid Dehydrogenase 1.
Clinical trials have demonstrated that male hormonal contraceptives can be effective, safe and reversible. The major component of the hormonal contraceptives is a long-acting testosterone. However, the use of androgen could generate side effects lowering HDL. Alternative use of androgen without these side effects could be beneficial. The present study is testing the efficacy of 11keto-testosterone (11KT) as androgen and its effects of 11β-hydroxysteroid dehydrogenase 1 (11βHSD1). 11βHSD1 oxidative and reductive activities were determined in rat intact Leydig and liver cells and COS1 cells transfected with human 11βHSD1 in the presence of various concentrations of 11KT. The luciferase activities of 11KT to stimulate androgen elements after confection with human androgen receptor and luciferase reporter were compared to dihydrotestosterone and testosterone. IC50s of 11KT inhibiting 11βHSD1 in intact Leydig and liver cells were 138 nM and 142 nM, respectively, while the EC50s of 11KT stimulating 11ΒHSD1 in intact Leydig and liver cells were 75 nM and 58 nM, respectively. 11KT stimulated 11βHSD1 oxidase and inhibited reductase in COS1 cells transfected with human 11βHSD1 with the same potency. 11KT competitively inhibited 11βHSD1 reductive activity, while it provided with NADP+ which stimulated 11βHSD1 oxidative activity. At 10 nM, 11KT increased luciferase significantly and its potency was between dihydrotestosterone and testosterone. The present study suggests that 11KT is potent androgen with novel characteristics that increase 11βHSD1 oxidase and inhibits 11βHSD1 reductase thus eliminating active glucocorticoids.
- 1 May 2008
- Published by Oxford University Press (OUP) in Biology of Reproduction
- Vol. 78 (Suppl_1) , 142
Open Access11Keto-Testosterone as Androgen Contraceptive with Anti-Metabolic Benefits by Modulating 11β-Hydroxysteroid Dehydrogenase 1.
Clinical trials have demonstrated that male hormonal contraceptives can be effective, safe and reversible. The major component of the hormonal contraceptives is a long-acting testosterone. However, the use of androgen could generate side effects lowering HDL. Alternative use of androgen without these side effects could be beneficial. The present study is testing the efficacy of 11keto-testosterone (11KT) as androgen and its effects of 11β-hydroxysteroid dehydrogenase 1 (11βHSD1). 11βHSD1 oxidative and reductive activities were determined in rat intact Leydig and liver cells and COS1 cells transfected with human 11βHSD1 in the presence of various concentrations of 11KT. The luciferase activities of 11KT to stimulate androgen elements after confection with human androgen receptor and luciferase reporter were compared to dihydrotestosterone and testosterone. IC50s of 11KT inhibiting 11βHSD1 in intact Leydig and liver cells were 138 nM and 142 nM, respectively, while the EC50s of 11KT stimulating 11ΒHSD1 in intact Leydig and liver cells were 75 nM and 58 nM, respectively. 11KT stimulated 11βHSD1 oxidase and inhibited reductase in COS1 cells transfected with human 11βHSD1 with the same potency. 11KT competitively inhibited 11βHSD1 reductive activity, while it provided with NADP+ which stimulated 11βHSD1 oxidative activity. At 10 nM, 11KT increased luciferase significantly and its potency was between dihydrotestosterone and testosterone. The present study suggests that 11KT is potent androgen with novel characteristics that increase 11βHSD1 oxidase and inhibits 11βHSD1 reductase thus eliminating active glucocorticoids.